Autoren Details

Sorwe Mojtahed Poor, Thomas Ulshöfer, Laureen Gabriel, Marina Henke, Michaela Köhm, Frank Behrens, Gerd Geisslinger, Michael J. Parnham, Harald Burkhardt, Susanne Schiffmann

Immunogenicity assay development and validation for biologic therapy as exemplified by ustekinumab

2019, Clinical & Experimental Immunology

Sabine Löhr, Steffen Uebe, Frank Behrens, Beate Bohm, Michaela Köhm, Heiko Traupe, Vinzenz Oji, Harald Burkhardt, André Reis, Ulrike Hüffmeier

Association analysis of psoriasis vulgaris and psoriatic arthritis with loss-of-function mutations in IL36RN in German patients

2018, British Journal of Dermatology

Frank Behrens, Diamant Thaci, Jürgen Wollenhaupt, Klaus Krueger

Psoriatic arthritis: Overview of drug therapy options and administration characteristics

2018, Zeitschrift fur Rheumatologie

Ronald F. van Vollenhoven, Edward Clark Keystone, Vibeke Strand, Cesar Pacheco-Tena, Jin Vencovsky, Frank Behrens, Arthur Racewicz, Daniela Zipp, Faiza Rharbaoui, Ralf Wolter, Luise Knierim, Rainer Schmeidl, Xuefei Zhou, Silke Aigner, Benjamin Dälken, Andrea Wartenberg-Demand

Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial

2018, Annals of the Rheumatic Diseases

Mark C. Genovese, Bernard Combe, Joel M. Kremer, Tsen-Fang Tsai, Frank Behrens, David H. Adams, Chin Lee, Lisa Kerr, Peter Nash

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2

2018, Rheumatology

Frank Behrens, Michaela Köhm, Eva C. Schwaneck Schwaneck, Marc Schmalzing, Holger Gnann, Gerg Greger, Hans-Peter Tony, Harald Burkhardt

Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab

2018, Rheumatology

Peter Nash, Frank Behrens, Ana-Marie Orbai, Suchitrita S. Rathmann, David H. Adams, Olivier Benichou, Atul Deodhar

Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibit

2018, Rheumatic & Musculoskeletal Diseases

Stephanie Dauth, Michaela Köhm, Tanja Rossmanith, Eva Hermann, Alexander Christoph Lehn, Harald Burkhardt, Frank Behrens

Value of combining biologics with methotrexate for treatment of psoriatic arthritis-questions remain

2018, Zeitschrift für Rheumatologie

Christoph Fiehn, Julia Holle, Christof Iking-Konert, Jan Leipe, Christiane Weseloh, Marc Frerix, Rieke Alten, Frank Behrens, Christoph G. O. Baerwald, Jürgen Braun, Helen Burkhardt, Gerd Burmester, Jacqueline Detert, Martin Gaubitz, Angela Gause, Herbert Kellner, Andreas Krause, Jens Gert Kuipers, Hanns-Martin Lorenz, Ulf Müller-Ladner, Monika Nothacker, Hubert Nüsslein, Andrea Rubbert-Roth, Matthias Schneider, Hendrik Schulze-Koops, Sebastian Seitz, Helmut Sitter, Christof Specker, Hans-Peter Tony, Siegfried Wassenberg, Jürgen Wollenhaupt, Klaus Krueger

S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs

2018, Zeitschrift für Rheumatologie

Frank Behrens, Lothar Meier, Jörg C. Prinz, Jürgen Jobst, Ralph Lippe, Peter-Andreas Löschmann, Hanns-Martin Lorenz

Simultaneous Response in Several Domains in Patients with Psoriatic Disease Treated with Etanercept as Monotherapy or in Combination with Conventional Synthetic Disease-modifying Antirheumatic Drugs

2018, The Journal of Rheumatology

Laure Gossec, Dennis McGonagle, Tatiana Korotaeva, Ennio Lubrano, Eugenio de Miguel, Mikkel Ostergaard, Frank Behrens

Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature

2018, The Journal of Rheumatology

Frank Behrens, Diamant Thaci, Jürgen Wollenhaupt, Klaus Krueger

[Psoriatic arthritis : Overview of drug therapy options and administration characteristics]

2017, Hautarzt

Ernest Choy, Daniel Aletaha, Frank Behrens, Axel Finckh, Juan Gomez-Reino, Jacques-Eric Gottenberg, Florian Schuch, Andrea Rubbert-Roth

Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis

2017, Rheumatology

Michaela Köhm, Frank Behrens

[Psoriatic arthritis : Current therapeutic standards]

2017, Zeitschrift für Rheumatologie

Fabian Proft, Hendrik Schulze-Koops, Mathias Grünke, Eva Vanessa Schrezenmeier, Fabian Halleck, Jörg Henes, Leonore Unger, Edgar Schmidt, Christoph Fiehn, Annett Jacobi, Christof Iking-Konert, Claudia Kneitz, Reinhold E. Schmidt, Bettina Bannert, Reinhard E. Voll, Rebecca Fischer-Betz, Ina Kötter, Hans-Peter Tony, Julia Holle, Martin Aringer, Anne Erler, Frank Behrens, Gerd Burmester, Thomas Dörner

[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)]

2017, Zeitschrift für Rheumatologie

Dafna D. Gladman, William Rigby, Valderilio F. Azevedo, Frank Behrens, Ricardo Blanco, Andrzej Kaszuba, Elizabeth Kudlacz, Cunshan Wang, Sujatha Menon, Thijs Hendrikx, Keith S. Kanik

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

2017, The New England Journal of Medicine

Steffen Uebe, Maria Ehrlicher, Arif B Ekici, Frank Behrens, Beate Bohm, Georg Homuth, Claudia Schurmann, Uwe Völker, Michael Jünger, Heiko Traupe, Michael Krawczak, Harald Burkhardt, André Reis, Ulrike Hüffmeier

Genome-wide association and targeted analysis of copy number variants with psoriatic arthritis in German patients

2017, BMC Medical Genetics

Frank Behrens, Michaela Köhm, Diamant Thaci, Holger Gnann, Gerg Greger, Bianca M. Wittig, Harald Burkhardt

Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis

2016, Rheumatology

Frank Behrens, Michaela Köhm, Uta Arndt, Gerg Greger, Diamant Thaci, Eva C Scharbatke, Hans-Peter Tony, Harald Burkhardt

Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study

2016, The Journal of Rheumatology

John Bowes, Sabine Löhr, Ashley Budu-Aggrey, Steffen Uebe, Ian N Bruce, Marie Feletar, Helena Marzo-Ortega, Philip S. Helliwell, Anthony W. Ryan, David Kane, Eleanor Korendowych, Gerd-Marie Alenius, Emiliano Giardiana, Jon Packham, Ross McManus, Oliver Fitzgerald, Matthew A. Brown, Frank Behrens, Harald Burkhardt, Neil McHugh, Ulrike Hüffmeier, Pauline Ho, André Reis, Anne Barton

PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus

2015, Annals of the rheumatic diseases

Michaela Köhm, Harald Burkhardt, Frank Behrens

Anti-TNFalpha-therapy as an evidence-based treatment option for different clinical manifestations of psoriatic arthritis

2015, Clinical and experimental rheumatology

John Bowes, Ashley Budu-Aggrey, Ulrike Hüffmeier, Steffen Uebe, Kathryn Audrey Steel, Harry Lidstone Hebert, Chris Wallace, Jonathon Massay, Ian N Bruce, James Bluett, Marie Feletar, Ann W. Morgan, Helena Marzo-Ortega, Gary Donohoe, Derek Morris, Philip S. Helliwell, Anthony W. Ryan, David Kane, Richard Warren, Eleanor Korendowych, Gerd-Marie Alenius, Emiliano Giardiana, Jon Packham, Ross McManus, Oliver Fitzgerald, Neil McHugh, Matthew A. Brown, Pauline Ho, Frank Behrens, Harald Burkhardt, André Reis, Anne Barton

Corrigendum: Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis

2015, Nature communications

Frank Behrens, Paul P. Tak, Mikkel Ostergaard, Rumen Stoilov, Piotr Wiland, Thomas W. Huizinga, Vadym Y. Berenfus, Stoyanka Vladeva, Jürgen Rech, Andrea Rubbert-Roth, Marius Korkosz, Dmitriy Rekalov, Igor A. Zupanets, Bo Jannik Ejbjerg, Jens Geiseler, Julia Fresenius, Roman P Korolkiewicz, Arndt J. Schottelius, Harald Burkhardt

MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial

2015, Annals of the rheumatic diseases

Michaela Köhm, Frank Behrens

Pharmacotherapy of psoriatic arthritis. Treatment recommendations against the background of limited evidence

2015, Zeitschrift für Rheumatologie

Martin Feuchtenberger, Stefan Kleinert, Eva C Scharbatke, Holger Gnann, Frank Behrens, Bianca M. Wittig, Gerg Greger, Hans-Peter Tony

The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis

2015, Clinical and experimental rheumatology

Frank Behrens, Juan D. Canete, Ignazio Olivieri, Arno W. R. van Kuijk, Neil McHugh, Bernard Combe

Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature

2015, Rheumatology

Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis

2015, Nature communications

Diamant Thaci, Frank Behrens, Gerg Greger, Harald Burkhardt, Holger Gnann, R. Schopf

Association between skin and joint involvement in patients with psoriatic arthritis treated with adalimumab: analysis of data from a German non-interventional study

2015, Dermatology

Philip J. Mease, Dafna D. Gladman, Kim A. Papp, Majed M. Khraishi, Diamant Thaci, Frank Behrens, Robert Northington, Joanne Fuiman, Eustratios Bananis, Robert Boggs, Daniel Alvarez

Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics

2013, Journal of the American Academy of Dermatology

Frank Behrens, Hans-Peter Tony, Rieke Alten, Stefan Kleinert, Eva C Scharbatke, Michaela Köhm, Holger Gnann, Johanna Tams, Gerg Greger, Harald Burkhardt

Development and validation of a new disease activity score in 28 joints-based treatment response criterion for rheumatoid arthritis

2013, Arthritis Care & Research

Maria Apel, Steffen Uebe, John Bowes, Emiliano Giardiana, Eleanor Korendowych, Kristina Juneblad, Francesca Pasutto, Arif B Ekici, Ross McManus, Pauline Ho, Ian N Bruce, Anthony W. Ryan, Frank Behrens, Beate Bohm, Heiko Traupe, Jörg Lohmann, Christian Gieger, Heinz-Erich Wichmann, Leonid Padyukov, Oliver Fitzgerald, Gerd-Marie Alenius, Neil McHugh, Giuseppe Novelli, Harald Burkhardt, André Reis, Ulrike Hüffmeier

Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis

2013, Arthritis & Rheumatology

Frank Behrens, Christoph Finkenwirth, Karel Pavelka, Jirí Stolfa, Alenka Sipek-Dolnicar, Diamant Thaci, Harald Burkhardt

Leflunomide in psoriatic arthritis: results from a large European prospective observational study

2013, Arthritis Care & Research

Frank Behrens, Michaela Köhm

Personalized medicine in cytokine-targeted therapy

2013, Enthält auch Ergebnisse für Z Rheumatology. Nur nach Z Rheumatol. suchen Suchergebnisse Zeitschrift für Rheumatologie

Dr. Frank Behrens

Contact Info

Publizierte Papers